{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Central+Nervous+System+Anomalies",
    "query": {
      "condition": "Central Nervous System Anomalies"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1682,
    "total_pages": 169,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Central+Nervous+System+Anomalies&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T22:35:32.151Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01597596",
      "title": "A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pompe Disease (Infantile-Onset)",
        "Glycogen Storage Disease Type II (GSD II)",
        "Glycogenosis 2",
        "Acid Maltase Deficiency"
      ],
      "interventions": [
        {
          "name": "alglucosidase alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "Up to 12 Months"
      },
      "enrollment_count": 4,
      "start_date": "2012-08",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-01-18",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Oakland, California • Gainsville, Florida + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597596"
    },
    {
      "nct_id": "NCT03109756",
      "title": "Single Dose Pharmacokinetic (PK) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Angelman Syndrome",
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "OV101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Healx AI",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 12,
      "start_date": "2017-04-03",
      "completion_date": "2017-11-28",
      "has_results": false,
      "last_update_posted_date": "2017-11-30",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Nashville, Tennessee",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03109756"
    },
    {
      "nct_id": "NCT05972629",
      "title": "A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Phenylketonuria"
      ],
      "interventions": [
        {
          "name": "SAR444836",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2023-08-07",
      "completion_date": "2030-04-02",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05972629"
    },
    {
      "nct_id": "NCT05130866",
      "title": "Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neurofibromatosis Type 2"
      ],
      "interventions": [
        {
          "name": "REC-2282",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Recursion Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2022-06-20",
      "completion_date": "2025-08-18",
      "has_results": false,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05130866"
    },
    {
      "nct_id": "NCT00661453",
      "title": "CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Spinal Muscular Atrophy Type I"
      ],
      "interventions": [
        {
          "name": "Valproic Acid and Levocarnitine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "2 Weeks to 12 Months"
      },
      "enrollment_count": 40,
      "start_date": "2008-04",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2015-06-15",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Detroit, Michigan • Durham, North Carolina + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00661453"
    },
    {
      "nct_id": "NCT00465270",
      "title": "Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cryptogenic Stroke"
      ],
      "interventions": [
        {
          "name": "AMPLATZER PFO Occluder",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care - Medical Management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 980,
      "start_date": "2003-08",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2019-02-18",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00465270"
    },
    {
      "nct_id": "NCT01416441",
      "title": "Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tourette's Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "7 Years to 18 Years"
      },
      "enrollment_count": 170,
      "start_date": "2011-10-19",
      "completion_date": "2014-03-13",
      "has_results": true,
      "last_update_posted_date": "2021-10-07",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 36,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01416441"
    },
    {
      "nct_id": "NCT01453283",
      "title": "Tabectedin to Treat Children and Adolescents With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "4 Years to 16 Years"
      },
      "enrollment_count": 12,
      "start_date": "2006-12-20",
      "completion_date": "2011-10-11",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01453283"
    },
    {
      "nct_id": "NCT00000373",
      "title": "Treatment of Obsessive-Compulsive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obsessive-Compulsive Disorder"
      ],
      "interventions": [
        {
          "name": "olanzapine + fluoxetine",
          "type": "DRUG"
        },
        {
          "name": "placebo + fluoxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "14 Years to 70 Years"
      },
      "enrollment_count": 74,
      "start_date": "1992-09",
      "completion_date": "2003-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-27",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Jacksonville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000373"
    },
    {
      "nct_id": "NCT07093541",
      "title": "Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Tourettes Disorder",
        "Tourette Disorder"
      ],
      "interventions": [
        {
          "name": "ecopipam HCl ~2mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emalex Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "6 Years to 50 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-07-22T22:35:32.151Z",
      "location_count": 26,
      "location_summary": "Glendale, California • San Rafael, California • New Haven, Connecticut + 18 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Rafael",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07093541"
    }
  ]
}